- Home
- VRDN
as 05-30-2025 4:00pm EST
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $38.50 | AVG Volume (30 days): | 838.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.90 - $27.20 | Next Earning Date: | 05-06-2025 |
| Revenue: | $302,000 | Revenue Growth: | 4.86% |
| Revenue Growth (this year): | -38.34% | Revenue Growth (next year): | 21976.14% |
Latest Viridian Therapeutics Inc. News
VRDN Breaking Stock News: Dive into VRDN Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Business Wire
12 days ago
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
Business Wire
24 days ago
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
Simply Wall St.
25 days ago
Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations
Business Wire
a month ago
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
Business Wire
a month ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
Business Wire
3 months ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare VRDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.